Cardiovascular diseases

This G-BA category includes all medicinal products for the prevention of stroke, heart attack, heart failure or venous thromboembolism such as pulmonary embolism or deep vein thrombosis, as well as antihypertensives.

To date, the G-BA has assessed 16 different medicinal products in 26 procedures, which in turn were divided into 35 subpopulations. When these subpopulations are weighted according to their share of the total number of patients in the resolution, there is a major additional benefit for 0% and a considerable additional benefit for 13.5% of the subpopulations. The G-BA has confirmed a minor additional benefit for 43% and a non-quantifiable additional benefit for another 0% in relation to the comparative treatment. The G-BA did recognise no additional benefit for 43.5% of the subpopulations, corresponding to 8% of the potential total number of all patients using these medicinal products.